Dataset

Bennett VHH design target Influenza Hemagglutinin

Influenza H1 haemagglutinin stem as a design target for the fine-tuned RFdiffusion VHH campaigns, with the epitope defined by the hotspot residues in Supplementary Methods Table 5.

Evaluation results

10 evaluations · 12 results. Different protocols are not a single leaderboard.

Filter evaluations

Tested model or methodProtocolDatasetEvaluation setupMetricEvidence origin

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configuration	Protocol and dataset	Finding	Evidence and details
Configuration: Fine-tuned RFdiffusion VHH design with fine-tuned RoseTTAFold2 filtering at hotspot proportion 1	Protocol: Bennett VHH design, E. coli expression and single-concentration SPR screen of 96 designs Dataset: Bennett VHH design target Influenza Hemagglutinin	1 Count (SPR-confirmed binders; initial screening method SPR) count · higher Uncertainty: Not applicable: An exact count. Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Evidence concern: excluded from comparisons The main text says 'at lower throughput with Escherichia coli expression and single-concentration surface plasmon resonance (SPR; 95 designs per target; TcdB, IL-7Ra and influenza haemagglutinin)', but Supplementary Methods Table 6 prints 96 designs screened for TcdB, IL7R and H1 stem. Table 6's value is recorded because it is the chosen table; the main text figure is 95.Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Results paragraph 2; Supplementary Methods Table 6, column 'Designs screened' Methods, coverage and source Fine-tuned RFdiffusion VHH design against H1 stem, E. coli expression and single-concentration SPR uc-binder-20261022-protocol-bennett-vhh-ecoli-spr-96 Aggregation: Not reported Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6; Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Supplementary Methods Table 6, row 'H1 stem' (Designs screened = 96), column 'SPR confirmed binders'
Configuration: Fine-tuned RFdiffusion VHH design with fine-tuned RoseTTAFold2 filtering at hotspot proportion 1	Protocol: Bennett VHH design, E. coli expression and single-concentration SPR screen of 96 designs Dataset: Bennett VHH design target Influenza Hemagglutinin	1% Hit rate (SPR-confirmed binders out of designs screened; initial screening method SPR) percent · higher Uncertainty: Not reported by the source: No interval is printed. Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Evidence concern: excluded from comparisons The main text says 'at lower throughput with Escherichia coli expression and single-concentration surface plasmon resonance (SPR; 95 designs per target; TcdB, IL-7Ra and influenza haemagglutinin)', but Supplementary Methods Table 6 prints 96 designs screened for TcdB, IL7R and H1 stem. Table 6's value is recorded because it is the chosen table; the main text figure is 95.Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Results paragraph 2; Supplementary Methods Table 6, column 'Designs screened' Methods, coverage and source Fine-tuned RFdiffusion VHH design against H1 stem, E. coli expression and single-concentration SPR uc-binder-20261022-protocol-bennett-vhh-ecoli-spr-96 Aggregation: Not reported Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6; Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Supplementary Methods Table 6, row 'H1 stem' (Designs screened = 96), column 'Success rate by SPR'
Configuration: Fine-tuned RFdiffusion VHH design with fine-tuned RoseTTAFold2 filtering at hotspot proportion 1	Protocol: Bennett VHH computational success rate under an AlphaFold3 filter Dataset: Bennett VHH design target Influenza Hemagglutinin	5% Success rate (AlphaFold3 filter) percent · higher Uncertainty: Not reported by the source: No interval is printed. Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Evidence concern: excluded from comparisons The main text says 'at lower throughput with Escherichia coli expression and single-concentration surface plasmon resonance (SPR; 95 designs per target; TcdB, IL-7Ra and influenza haemagglutinin)', but Supplementary Methods Table 6 prints 96 designs screened for TcdB, IL7R and H1 stem. Table 6's value is recorded because it is the chosen table; the main text figure is 95.Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Results paragraph 2; Supplementary Methods Table 6, column 'Designs screened' Methods, coverage and source Fine-tuned RFdiffusion VHH computational success rate against H1 stem, AlphaFold3 filter uc-binder-20261022-protocol-bennett-insilico-af3-success Aggregation: Not reported Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6; Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Supplementary Methods Table 6, row 'H1 stem' (Designs screened = 96), column 'Success rate (%) (AF3)'
Configuration: Fine-tuned RFdiffusion VHH design with fine-tuned RoseTTAFold2 filtering at hotspot proportion 1	Protocol: Bennett VHH computational success rate under the fine-tuned RoseTTAFold2 filter Dataset: Bennett VHH design target Influenza Hemagglutinin	3.5% Success rate (fine-tuned RoseTTAFold2 filter, hotspot proportion 0.0) percent · higher Uncertainty: Not reported by the source: No interval is printed. Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Evidence concern: excluded from comparisons The main text says 'at lower throughput with Escherichia coli expression and single-concentration surface plasmon resonance (SPR; 95 designs per target; TcdB, IL-7Ra and influenza haemagglutinin)', but Supplementary Methods Table 6 prints 96 designs screened for TcdB, IL7R and H1 stem. Table 6's value is recorded because it is the chosen table; the main text figure is 95.Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Results paragraph 2; Supplementary Methods Table 6, column 'Designs screened' Methods, coverage and source Fine-tuned RFdiffusion VHH computational success rate against H1 stem, fine-tuned RoseTTAFold2 filter, hotspot proportion 0.0 uc-binder-20261022-protocol-bennett-insilico-rf2-success Aggregation: Not reported Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6; Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Supplementary Methods Table 6, row 'H1 stem' (Designs screened = 96), column 'Success rate (%) (RF2, hotspot proportion = 0.0)'
Configuration: Fine-tuned RFdiffusion VHH design with fine-tuned RoseTTAFold2 filtering at hotspot proportion 1	Protocol: Bennett VHH computational success rate under the fine-tuned RoseTTAFold2 filter Dataset: Bennett VHH design target Influenza Hemagglutinin	7.5% Success rate (fine-tuned RoseTTAFold2 filter, hotspot proportion 0.1) percent · higher Uncertainty: Not reported by the source: No interval is printed. Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Evidence concern: excluded from comparisons The main text says 'at lower throughput with Escherichia coli expression and single-concentration surface plasmon resonance (SPR; 95 designs per target; TcdB, IL-7Ra and influenza haemagglutinin)', but Supplementary Methods Table 6 prints 96 designs screened for TcdB, IL7R and H1 stem. Table 6's value is recorded because it is the chosen table; the main text figure is 95.Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Results paragraph 2; Supplementary Methods Table 6, column 'Designs screened' Methods, coverage and source Fine-tuned RFdiffusion VHH computational success rate against H1 stem, fine-tuned RoseTTAFold2 filter, hotspot proportion 0.1 uc-binder-20261022-protocol-bennett-insilico-rf2-success Aggregation: Not reported Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6; Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Supplementary Methods Table 6, row 'H1 stem' (Designs screened = 96), column 'Success rate (%) (RF2, hotspot proportion = 0.1)'
Configuration: Fine-tuned RFdiffusion VHH design with fine-tuned RoseTTAFold2 filtering at hotspot proportion 1	Protocol: Bennett VHH computational success rate under the fine-tuned RoseTTAFold2 filter Dataset: Bennett VHH design target Influenza Hemagglutinin	11.5% Success rate (fine-tuned RoseTTAFold2 filter, hotspot proportion 1) percent · higher Uncertainty: Not reported by the source: No interval is printed. Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Evidence concern: excluded from comparisons The main text says 'at lower throughput with Escherichia coli expression and single-concentration surface plasmon resonance (SPR; 95 designs per target; TcdB, IL-7Ra and influenza haemagglutinin)', but Supplementary Methods Table 6 prints 96 designs screened for TcdB, IL7R and H1 stem. Table 6's value is recorded because it is the chosen table; the main text figure is 95.Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Results paragraph 2; Supplementary Methods Table 6, column 'Designs screened' Methods, coverage and source Fine-tuned RFdiffusion VHH computational success rate against H1 stem, fine-tuned RoseTTAFold2 filter, hotspot proportion 1 uc-binder-20261022-protocol-bennett-insilico-rf2-success Aggregation: Not reported Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6; Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Supplementary Methods Table 6, row 'H1 stem' (Designs screened = 96), column 'Success rate (%) (RF2, hotspot proportion = 1)'
Configuration: Fine-tuned RFdiffusion VHH design with fine-tuned RoseTTAFold2 filtering at hotspot proportion 1	Protocol: Bennett VHH design, yeast surface display screen of 9,000 designs with SPR confirmation Dataset: Bennett VHH design target Influenza Hemagglutinin	20 Count (SPR-confirmed binders; initial screening method YSD) count · higher Uncertainty: Not applicable: An exact count. Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Evidence concern: excluded from comparisons The main text says 'at lower throughput with Escherichia coli expression and single-concentration surface plasmon resonance (SPR; 95 designs per target; TcdB, IL-7Ra and influenza haemagglutinin)', but Supplementary Methods Table 6 prints 96 designs screened for TcdB, IL7R and H1 stem. Table 6's value is recorded because it is the chosen table; the main text figure is 95.Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Results paragraph 2; Supplementary Methods Table 6, column 'Designs screened' Methods, coverage and source Fine-tuned RFdiffusion VHH design against H1 stem, yeast surface display with SPR confirmation uc-binder-20261022-protocol-bennett-vhh-yeast-display-9000 Aggregation: Not reported Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6; Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Supplementary Methods Table 6, row 'H1 stem' (Designs screened = 9000), column 'SPR confirmed binders'
Configuration: Fine-tuned RFdiffusion VHH design with fine-tuned RoseTTAFold2 filtering at hotspot proportion 1	Protocol: Bennett VHH design, yeast surface display screen of 9,000 designs with SPR confirmation Dataset: Bennett VHH design target Influenza Hemagglutinin	0.2% Hit rate (SPR-confirmed binders out of designs screened; initial screening method YSD) percent · higher Uncertainty: Not reported by the source: No interval is printed. Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Evidence concern: excluded from comparisons The main text says 'at lower throughput with Escherichia coli expression and single-concentration surface plasmon resonance (SPR; 95 designs per target; TcdB, IL-7Ra and influenza haemagglutinin)', but Supplementary Methods Table 6 prints 96 designs screened for TcdB, IL7R and H1 stem. Table 6's value is recorded because it is the chosen table; the main text figure is 95.Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Results paragraph 2; Supplementary Methods Table 6, column 'Designs screened' Methods, coverage and source Fine-tuned RFdiffusion VHH design against H1 stem, yeast surface display with SPR confirmation uc-binder-20261022-protocol-bennett-vhh-yeast-display-9000 Aggregation: Not reported Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6; Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Supplementary Methods Table 6, row 'H1 stem' (Designs screened = 9000), column 'Success rate by SPR'
Configuration: Fine-tuned RFdiffusion VHH design with fine-tuned RoseTTAFold2 filtering at hotspot proportion 1	Protocol: Bennett VHH computational success rate under an AlphaFold3 filter Dataset: Bennett VHH design target Influenza Hemagglutinin	5% Success rate (AlphaFold3 filter) percent · higher Uncertainty: Not reported by the source: No interval is printed. Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Evidence concern: excluded from comparisons The main text says 'at lower throughput with Escherichia coli expression and single-concentration surface plasmon resonance (SPR; 95 designs per target; TcdB, IL-7Ra and influenza haemagglutinin)', but Supplementary Methods Table 6 prints 96 designs screened for TcdB, IL7R and H1 stem. Table 6's value is recorded because it is the chosen table; the main text figure is 95.Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Results paragraph 2; Supplementary Methods Table 6, column 'Designs screened' Methods, coverage and source Fine-tuned RFdiffusion VHH computational success rate against H1 stem, AlphaFold3 filter uc-binder-20261022-protocol-bennett-insilico-af3-success Aggregation: Not reported Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6; Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Supplementary Methods Table 6, row 'H1 stem' (Designs screened = 9000), column 'Success rate (%) (AF3)'
Configuration: Fine-tuned RFdiffusion VHH design with fine-tuned RoseTTAFold2 filtering at hotspot proportion 1	Protocol: Bennett VHH computational success rate under the fine-tuned RoseTTAFold2 filter Dataset: Bennett VHH design target Influenza Hemagglutinin	(3.5)% Success rate (fine-tuned RoseTTAFold2 filter, hotspot proportion 0.0; value printed in parentheses because it repeats the 96-design row from the same design campaign) percent · higher Uncertainty: Not reported by the source: No interval is printed. Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Evidence concern: excluded from comparisons The main text says 'at lower throughput with Escherichia coli expression and single-concentration surface plasmon resonance (SPR; 95 designs per target; TcdB, IL-7Ra and influenza haemagglutinin)', but Supplementary Methods Table 6 prints 96 designs screened for TcdB, IL7R and H1 stem. Table 6's value is recorded because it is the chosen table; the main text figure is 95.Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Results paragraph 2; Supplementary Methods Table 6, column 'Designs screened' Methods, coverage and source Fine-tuned RFdiffusion VHH computational success rate against H1 stem, fine-tuned RoseTTAFold2 filter, hotspot proportion 0.0 uc-binder-20261022-protocol-bennett-insilico-rf2-success Aggregation: Not reported Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6; Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Supplementary Methods Table 6, row 'H1 stem' (Designs screened = 9000), column 'Success rate (%) (RF2, hotspot proportion = 0.0)'
Configuration: Fine-tuned RFdiffusion VHH design with fine-tuned RoseTTAFold2 filtering at hotspot proportion 1	Protocol: Bennett VHH computational success rate under the fine-tuned RoseTTAFold2 filter Dataset: Bennett VHH design target Influenza Hemagglutinin	(7.5)% Success rate (fine-tuned RoseTTAFold2 filter, hotspot proportion 0.1; value printed in parentheses because it repeats the 96-design row from the same design campaign) percent · higher Uncertainty: Not reported by the source: No interval is printed. Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Evidence concern: excluded from comparisons The main text says 'at lower throughput with Escherichia coli expression and single-concentration surface plasmon resonance (SPR; 95 designs per target; TcdB, IL-7Ra and influenza haemagglutinin)', but Supplementary Methods Table 6 prints 96 designs screened for TcdB, IL7R and H1 stem. Table 6's value is recorded because it is the chosen table; the main text figure is 95.Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Results paragraph 2; Supplementary Methods Table 6, column 'Designs screened' Methods, coverage and source Fine-tuned RFdiffusion VHH computational success rate against H1 stem, fine-tuned RoseTTAFold2 filter, hotspot proportion 0.1 uc-binder-20261022-protocol-bennett-insilico-rf2-success Aggregation: Not reported Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6; Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Supplementary Methods Table 6, row 'H1 stem' (Designs screened = 9000), column 'Success rate (%) (RF2, hotspot proportion = 0.1)'
Configuration: Fine-tuned RFdiffusion VHH design with fine-tuned RoseTTAFold2 filtering at hotspot proportion 1	Protocol: Bennett VHH computational success rate under the fine-tuned RoseTTAFold2 filter Dataset: Bennett VHH design target Influenza Hemagglutinin	(11.5)% Success rate (fine-tuned RoseTTAFold2 filter, hotspot proportion 1; value printed in parentheses because it repeats the 96-design row from the same design campaign) percent · higher Uncertainty: Not reported by the source: No interval is printed. Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Evidence concern: excluded from comparisons The main text says 'at lower throughput with Escherichia coli expression and single-concentration surface plasmon resonance (SPR; 95 designs per target; TcdB, IL-7Ra and influenza haemagglutinin)', but Supplementary Methods Table 6 prints 96 designs screened for TcdB, IL7R and H1 stem. Table 6's value is recorded because it is the chosen table; the main text figure is 95.Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Results paragraph 2; Supplementary Methods Table 6, column 'Designs screened' Methods, coverage and source Fine-tuned RFdiffusion VHH computational success rate against H1 stem, fine-tuned RoseTTAFold2 filter, hotspot proportion 1 uc-binder-20261022-protocol-bennett-insilico-rf2-success Aggregation: Not reported Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6; Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Supplementary Methods Table 6, row 'H1 stem' (Designs screened = 9000), column 'Success rate (%) (RF2, hotspot proportion = 1)'

Source checking is not independent reproduction. Release 2026-10-22-1b7cf027e4f6.

Research readiness

0 of 4 readiness checks met. These checks assess whether the evidence supports a reproducible investigation; a source-checked score alone does not meet them.

Readiness checks, gaps and artifacts

Release 2026-10-22-1b7cf027e4f6 · Evidence verified: Not verified

Evidence incomplete

Replay metrics

Exact outcomes, predictions, identifiers and evaluator are connected.

Missing or unresolved evidence

No verified artifact manifest is linked to this exact record.
File checksums match the recorded files: not yet verified
Predictions are matched to the right samples: not yet verified
Score meaning and direction are confirmed: not yet verified
Metrics are recomputed from the saved predictions: not yet verified

Verified: Not verified

Evidence incomplete

Investigate discrepancies

Replay evidence includes annotations and an assessment of dependence. Unknown independence permits descriptive analysis only.

Missing or unresolved evidence

No verified artifact manifest is linked to this exact record.
File checksums match the recorded files: not yet verified
Predictions are matched to the right samples: not yet verified
Score meaning and direction are confirmed: not yet verified
Metrics are recomputed from the saved predictions: not yet verified
Sample annotations are recorded: not yet verified
Dependence between samples is assessed: not yet verified

Verified: Not verified

Evidence incomplete

Run locally

A pinned recipe describes the inputs, environment and resource requirements.

Missing or unresolved evidence

No verified artifact manifest is linked to this exact record.
File checksums match the recorded files: not yet verified
Predictions are matched to the right samples: not yet verified
Score meaning and direction are confirmed: not yet verified
A pinned run recipe exists: not yet verified
Compute requirements are estimated: not yet verified

Verified: Not verified

Evidence incomplete

Validate independently

Separate data and exposure records support an independent test.

Missing or unresolved evidence

No verified artifact manifest is linked to this exact record.
File checksums match the recorded files: not yet verified
Predictions are matched to the right samples: not yet verified
Score meaning and direction are confirmed: not yet verified
Independent validation data exist: not yet verified
Overlap with training data is checked: not yet verified

Verified: Not verified

Readiness describes the evidence in this release. Availability on your computer is checked separately when an investigation runs. Existing data exposure can prevent independent validation even when files are available.

Artifacts and reproduction

No verified artifact manifest is connected to this record yet. The gaps above identify what is needed before analysis can begin.

Dataset and evaluation context

A dataset supplies biological observations. The evaluation protocol defines how those observations are split, used and scored.

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

16 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-10-22-1b7cf027e4f6
Property and statement	Original source and location	Review and provenance
Accession 5VLI Context-only references	Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) Original source ↗ Supplementary Methods Table 5, row 'Influenza Hemagglutinin' Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Nature, version of record; Europe PMC JATS full text for PMC12727541 Retrieved: 2026-10-22T11:55:00Z	not individually reviewed No individual claim review recorded Source has a recorded evidence concern. Consult its source page before using the claim. Audit details Field: `attributes.accession` Source artifact SHA-256: `d7876bc73c47f2cb3fcb0fa1ef917c89c9b67750a22f6402bf515f978cd1564a` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
Accession 5VLI Context-only references	Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6 Original source ↗ Supplementary Methods Table 5, row 'Influenza Hemagglutinin' Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Supplementary Information PDF 41586_2025_9721_MOESM1_ESM.pdf, 129 pages, InDesign 17.4, ModDate 2026-09-15 Retrieved: 2026-10-22T12:05:00Z	not individually reviewed No individual claim review recorded Audit details Field: `attributes.accession` Source artifact SHA-256: `f5d4fc4f3a65a2dc3ab696e165bb86bf150b2437cdc1a7046cfbecae8ccab05c` Hash scope: SHA-256 of the Supplementary Information PDF as extracted from one retrieval of the supplementary archive on 2026-10-22. The archive itself was truncated (103,690,987 bytes, SHA-256 6b1bd61ba4d69d5393f56e0e0d12bb4349b45ce12496a1d3e6a5a8467c39203a) and is not the pinned artifact. Archive member: 41586_2025_9721_MOESM1_ESM.pdf, extracted from the Europe PMC supplementaryFiles archive for PMC12727541 Inspected artifact
Population VHH designs generated against the stated epitope of Influenza Hemagglutinin Context-only references	Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) Original source ↗ Supplementary Methods Table 5, row 'Influenza Hemagglutinin' Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Nature, version of record; Europe PMC JATS full text for PMC12727541 Retrieved: 2026-10-22T11:55:00Z	not individually reviewed No individual claim review recorded Source has a recorded evidence concern. Consult its source page before using the claim. Audit details Field: `attributes.population` Source artifact SHA-256: `d7876bc73c47f2cb3fcb0fa1ef917c89c9b67750a22f6402bf515f978cd1564a` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
Population VHH designs generated against the stated epitope of Influenza Hemagglutinin Context-only references	Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6 Original source ↗ Supplementary Methods Table 5, row 'Influenza Hemagglutinin' Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Supplementary Information PDF 41586_2025_9721_MOESM1_ESM.pdf, 129 pages, InDesign 17.4, ModDate 2026-09-15 Retrieved: 2026-10-22T12:05:00Z	not individually reviewed No individual claim review recorded Audit details Field: `attributes.population` Source artifact SHA-256: `f5d4fc4f3a65a2dc3ab696e165bb86bf150b2437cdc1a7046cfbecae8ccab05c` Hash scope: SHA-256 of the Supplementary Information PDF as extracted from one retrieval of the supplementary archive on 2026-10-22. The archive itself was truncated (103,690,987 bytes, SHA-256 6b1bd61ba4d69d5393f56e0e0d12bb4349b45ce12496a1d3e6a5a8467c39203a) and is not the pinned artifact. Archive member: 41586_2025_9721_MOESM1_ESM.pdf, extracted from the Europe PMC supplementaryFiles archive for PMC12727541 Inspected artifact
Reported name Influenza Hemagglutinin Context-only references	Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) Original source ↗ Supplementary Methods Table 5, row 'Influenza Hemagglutinin' Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Nature, version of record; Europe PMC JATS full text for PMC12727541 Retrieved: 2026-10-22T11:55:00Z	not individually reviewed No individual claim review recorded Source has a recorded evidence concern. Consult its source page before using the claim. Audit details Field: `attributes.reported_name` Source artifact SHA-256: `d7876bc73c47f2cb3fcb0fa1ef917c89c9b67750a22f6402bf515f978cd1564a` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
Reported name Influenza Hemagglutinin Context-only references	Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6 Original source ↗ Supplementary Methods Table 5, row 'Influenza Hemagglutinin' Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Supplementary Information PDF 41586_2025_9721_MOESM1_ESM.pdf, 129 pages, InDesign 17.4, ModDate 2026-09-15 Retrieved: 2026-10-22T12:05:00Z	not individually reviewed No individual claim review recorded Audit details Field: `attributes.reported_name` Source artifact SHA-256: `f5d4fc4f3a65a2dc3ab696e165bb86bf150b2437cdc1a7046cfbecae8ccab05c` Hash scope: SHA-256 of the Supplementary Information PDF as extracted from one retrieval of the supplementary archive on 2026-10-22. The archive itself was truncated (103,690,987 bytes, SHA-256 6b1bd61ba4d69d5393f56e0e0d12bb4349b45ce12496a1d3e6a5a8467c39203a) and is not the pinned artifact. Archive member: 41586_2025_9721_MOESM1_ESM.pdf, extracted from the Europe PMC supplementaryFiles archive for PMC12727541 Inspected artifact
Scope note Supplementary Methods Table 5, row 'Influenza Hemagglutinin': PDB accession '5VLI'; hotspot residues 'B521, B545, B552'. The target was used in cropped form during design. Context-only references	Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) Original source ↗ Supplementary Methods Table 5, row 'Influenza Hemagglutinin' Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Nature, version of record; Europe PMC JATS full text for PMC12727541 Retrieved: 2026-10-22T11:55:00Z	not individually reviewed No individual claim review recorded Source has a recorded evidence concern. Consult its source page before using the claim. Audit details Field: `attributes.scope_note` Source artifact SHA-256: `d7876bc73c47f2cb3fcb0fa1ef917c89c9b67750a22f6402bf515f978cd1564a` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
Scope note Supplementary Methods Table 5, row 'Influenza Hemagglutinin': PDB accession '5VLI'; hotspot residues 'B521, B545, B552'. The target was used in cropped form during design. Context-only references	Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6 Original source ↗ Supplementary Methods Table 5, row 'Influenza Hemagglutinin' Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Supplementary Information PDF 41586_2025_9721_MOESM1_ESM.pdf, 129 pages, InDesign 17.4, ModDate 2026-09-15 Retrieved: 2026-10-22T12:05:00Z	not individually reviewed No individual claim review recorded Audit details Field: `attributes.scope_note` Source artifact SHA-256: `f5d4fc4f3a65a2dc3ab696e165bb86bf150b2437cdc1a7046cfbecae8ccab05c` Hash scope: SHA-256 of the Supplementary Information PDF as extracted from one retrieval of the supplementary archive on 2026-10-22. The archive itself was truncated (103,690,987 bytes, SHA-256 6b1bd61ba4d69d5393f56e0e0d12bb4349b45ce12496a1d3e6a5a8467c39203a) and is not the pinned artifact. Archive member: 41586_2025_9721_MOESM1_ESM.pdf, extracted from the Europe PMC supplementaryFiles archive for PMC12727541 Inspected artifact
Source location Supplementary Methods Table 5, row 'Influenza Hemagglutinin' Context-only references	Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) Original source ↗ Supplementary Methods Table 5, row 'Influenza Hemagglutinin' Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Nature, version of record; Europe PMC JATS full text for PMC12727541 Retrieved: 2026-10-22T11:55:00Z	not individually reviewed No individual claim review recorded Source has a recorded evidence concern. Consult its source page before using the claim. Audit details Field: `attributes.source_locator` Source artifact SHA-256: `d7876bc73c47f2cb3fcb0fa1ef917c89c9b67750a22f6402bf515f978cd1564a` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
Source location Supplementary Methods Table 5, row 'Influenza Hemagglutinin' Context-only references	Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6 Original source ↗ Supplementary Methods Table 5, row 'Influenza Hemagglutinin' Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Supplementary Information PDF 41586_2025_9721_MOESM1_ESM.pdf, 129 pages, InDesign 17.4, ModDate 2026-09-15 Retrieved: 2026-10-22T12:05:00Z	not individually reviewed No individual claim review recorded Audit details Field: `attributes.source_locator` Source artifact SHA-256: `f5d4fc4f3a65a2dc3ab696e165bb86bf150b2437cdc1a7046cfbecae8ccab05c` Hash scope: SHA-256 of the Supplementary Information PDF as extracted from one retrieval of the supplementary archive on 2026-10-22. The archive itself was truncated (103,690,987 bytes, SHA-256 6b1bd61ba4d69d5393f56e0e0d12bb4349b45ce12496a1d3e6a5a8467c39203a) and is not the pinned artifact. Archive member: 41586_2025_9721_MOESM1_ESM.pdf, extracted from the Europe PMC supplementaryFiles archive for PMC12727541 Inspected artifact

How to read the evidence

Sources and history

Release 2026-10-22-1b7cf027e4f6 · Record review: source checked

2 source records and release history

Atomically accurate de novo design of antibodies with RFdiffusion (Bennett et al., Nature 2025) · Original source · Nature, version of record; Europe PMC JATS full text for PMC12727541
Bennett 2025 Supplementary Information, including Supplementary Methods Tables 5 and 6 · Original source · Supplementary Information PDF 41586_2025_9721_MOESM1_ESM.pdf, 129 pages, InDesign 17.4, ModDate 2026-09-15

Download this release (gzip)

Technical metadata and extraction receipts

Stable ID: uc-binder-20261022-data-bennett-h1stem

areas: proteins-complexes; protein-structure
contexts: research
accession: 5VLI
population: VHH designs generated against the stated epitope of Influenza Hemagglutinin
reported name: Influenza Hemagglutinin
review: artifact sha256: d7876bc73c47f2cb3fcb0fa1ef917c89c9b67750a22f6402bf515f978cd1564a; method: source-hash-verification; independent-cell-check; ai-assisted-source-review; method note: Re-downloaded from Europe PMC (HTTP 200, 169,840 bytes) and the SHA-256 recomputed and matched. Own flattening of the JATS XML. The main text's '95 designs per target' was confirmed verbatim and the string '96 designs' does not occur, so the conflict with Supplementary Methods Table 6 is real.; note: Reviewed in docs/reviews/use-cases/binder-2026-10-22.md. Automated AI review of the source transcription only; it is not human scientific review and nothing here was reproduced experimentally.; retrieval url: https://www.ebi.ac.uk/europepmc/webservices/rest/PMC12727541/fullTextXML; reviewed at: 2026-10-22T15:00:00Z; reviewer: claude; reviewer note: Claude review agent, independent of the extraction agent; no human review claimed
scope note: Supplementary Methods Table 5, row 'Influenza Hemagglutinin': PDB accession '5VLI'; hotspot residues 'B521, B545, B552'. The target was used in cropped form during design.
source locator: Supplementary Methods Table 5, row 'Influenza Hemagglutinin'
version: Supplementary Methods Table 5, Nature 2025 version of record

Related records

Suggest a correction